Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer
Hirotsugu Kenmotsu(Shizuoka Cancer Center), Masahiro Tsuboi(National Cancer Center Hospital East), Kenji Sugio(University of Occupational and Environmental Health Japan), Shinichi Toyooka(Okayama University Hospital), Yuichi Takiguchi(Sanno Medical Center), Toshihiro Misumi(Yokohama City University), Nobuyuki Yamamoto(Wakayama Medical University), Haruhiro Saito(Kanagawa Cancer Center), Kiyotaka Yoh(National Cancer Center Hospital East), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Hiroshi Date(Kyoto University), Shunichi Sugawara(Sendai Kousei Hospital), Tetsuya Mitsudomi(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kohei Yokoi(The University of Osaka), Hideo Saka(Nagoya Medical Center), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Koji Yamazaki, Isamu Okamoto(Kyushu University), Toshiaki Takahashi(Okayama University)
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k